晚期卵巢癌集中化初始治疗后无病生存和相对生存增加
基于瑞典妇科癌症质量登记库的 population-based 队列研究,纳入495例FIGO III–IV期上皮性卵巢癌和输卵管癌患者,比较2011年集中化初始治疗实施前后(2008–2010年244例 vs 2011–2013年251例)的5年无病生存(DFS)和相对生存(RS)。集中化后5年RS从24%(95%CI:19–31)升至37%(95%CI:31–44),中位RS从27个月(95%CI:23–34)升至44个月(95%CI:40–52),p<0.001;5年DFS显著延长,风险比0.77(95%CI:0.64–0.93),集中化为RS和DFS的独立显著因素。
要点
- 集中化后5年相对生存从24%(95%CI:19–31)升至37%(95%CI:31–44),中位相对生存从27个月(95%CI:23–34)升至44个月(95%CI:40–52),p<0.001。
- 2011–2013年较2008–2010年超额死亡率比(EMRR)为0.62(95%CI:0.51–0.76)。
- 集中化后5年无病生存显著延长,风险比0.77(95%CI:0.64–0.93),集中化为生存和无病生存的独立显著因素。
核心结论
- 晚期卵巢癌初始治疗集中化与完全细胞减灭率、5年相对生存和无病生存显著增加相关,且集中化是相对生存和无病生存的独立显著因素。
研究设计与样本
- 基于瑞典妇科癌症质量登记库(SQRGC)的 population-based 队列研究,纳入FIGO III期和IV期上皮性卵巢癌及输卵管癌女性,分为集中化前(2008–2010年,244例)和集中化后(2011–2013年,251例)两个队列,共495例。
主要发现
- 集中化后5年相对生存从24%(95%CI:19–31)升至37%(95%CI:31–44),中位相对生存从27个月(95%CI:23–34)升至44个月(95%CI:40–52),p<0.001(log-rank),该结果在总队列中 regardless of primary treatment。
- 2011–2013年较2008–2010年所有患者的超额死亡率比(EMRR)为0.62(95%CI:0.51–0.76)。
- 集中化后5年无病生存显著延长,风险比0.77(95%CI:0.64–0.93),集中化是生存和无病生存的独立显著因素。
- 完全细胞减灭是与相对生存和无病生存增加相关的显著独立因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze 5-year disease-free survival (DFS) and relative survival (RS) before and after the 2011 implementation of centralized primary treatment of patients with advanced ovarian cancer. METHODS: A population-based cohort study using the Swedish Quality Registry for Gynecological Cancer (SQRGC). Women with FIGO stage III and IV epithelial ovarian and Fallopian tube cancers were divided into two cohorts: before and after centralization. We estimated RS using the Ederer II method, analyzed the difference in the excess mortality rate ratio (EMRR) and estimated 5-year DFS in a Cox proportional hazard regression model with centralization, age, primary treatment and complete cytoreduction as variables. RESULTS: A total of 495 women were identified with 244 women before (2008-2010) and 251 after (2011-2013) centralization. An increased 5-year RS from 24% (95%CI:19-31) to 37% (95%CI:31-44) and an increased median RS from 27 months (95%CI:23-34) to 44 months (95%CI:40-52), p < 0.001 (log-rank), were observed in the total cohort regardless of primary treatment. EMRR was found to be 0.62 (95%CI:0.51-0.76) in 2011-2013 compared to 2008-2010 for all patients. After centralization, 5-year DFS was significantly longer, hazard ratio of 0.77 (95%CI:0.64-0.93) and centralization was found to be an independent significant factor for both survival and DFS. Complete cytoreduction was found to be a significant independent factor associated with increased RS and DFS. CONCLUSION: Centralization of primary treatment of advanced ovarian cancer was associated with significantly increased complete cytoreduction, 5-year RS and DFS, and was found to be a significant independent factor for both RS and DFS.
引用
- Palmqvist C, Staf C, Mateoiu C, et al. Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment. Gynecol Oncol. 2020. PMID: 32943206. doi:10.1016/j.ygyno.2020.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。